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greater susceptibility to invasive aspergillosis. T-cell secreted cytokine
response to aspergillus antigen in culture may be used to predict
patients’ ability to generate an immune response or can be associated
with disease progression. The production of -IFN is associated with
Th1 cell mediated immunity and results in greater resistance to
antigens. Production of Th2 cytokines, IL-10 and IL-4, indicates
immunosuppression and tolerance. T-cell secreted cytokines can be
detected using conventional enzyme-linked immunoassay (ELISA)
technology. The cytokine proﬁle produced during culture with as-
pergillus antigen may provide useful information on a patients ability
to mount an immune response to this speciﬁc antigen. Method: A.
fumigatus conidia were inoculated into Sabourad broth and incubated
for 42hours under appropriate conditions. The mycelial mat formed
was washed, disrupted with a homogenizer and cellular extract col-
lected. Protein content was determined using BSA standard. Antigen
was cultured initially with Ficolled mononuclear cells (MNCs) from
healthy normal donors to determine the minimum dose resulting in
best cytokine response. MNCs from patients at 3 and 6 month time
points after unrelated allogeneic transplantation were cultured withA.
fumigatus antigen at a concentration of 1  106 cells/ml. Cultures
were incubated at 37°C with 5% CO2 for 16-24 hours, centrifuged,
supernatant removed and frozen at 70°C until testing. IL-2, IL-4,
IL-10 and -IFN 96 well plate ELISA assays were performed on
thawed supernatants. Results: In patients who had undergone allo-
geneic transplants, 22 of 30 (73%) had higher IL-10/-IFN ratios
(34.0; range 0.03-486.7) at 3 months post transplant. In contrast, at 6
months, 8 of 14 (57%) had a higher IL-10/-IFN ratio (27.1; range
0.03-217.8). IL-2 secretion was undetectable in all 3 and 6 month post
transplant samples. Conclusions: Higher IL-10/-IFN ratios in pa-
tients at 3 months post-allogeneic transplant suggests a Th2 or more
immunosuppressive response to aspergillus. At 6 months post-trans-
plant, the average IL-10/-IFN ratio decreases which suggests an
increase in the number of patients able to demonstrate a Th1 cell
mediated immune response to A. fumigatus.
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DISEASE STATUS AT TRANSPLANT IMPACTS LYMPHOCYTE AND PLATE-
LET RECOVERY AFTER ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANT (PBSCT) FOR PATIENTS WITH AML/MDS
Saliba, R.M.1, Oran, B.1, Giralt, S.1, Komanduri, K.1,
Carrasco-Yalan, A.2, Ghosh, S.1, Champlin, R.1, de Lima, M.1 1.
Department of Blood and Marrow Transplantation, U.T. M.D. Ander-
son Cancer Center, Houston, TX; 2. CECLA, Mexico.
Lymphocyte and platelet count have been correlated with outcomes
of allogeneic SCT. We sought to test this hypothesis in a homoge-
neous group of patients with AML/MDS. Patients andMethods: 54
consecutive patients with high-risk AML/MDS received a matched-
sibling PBSCT with ﬂudarabine (100-180 mg/m2) and melphalan
(100-180mg/m2) conditioning and tacrolimus-basedGVHDprophy-
laxis between 1996 and 2003. Median age was 55 years (23-68).
Disease status at PBSCT was complete remission (CR, 15/54), No
CR with (NoCR/CB, 15/54) or without circulating blasts (NoCR/
NoCB, 24/54). Cytogenetics were high-risk in 45% of patients, in-
termediate in 46%, unknown in 9%. Cox’s regression analysis was
used to evaluate predictors of outcome at landmarks starting at day 30
post-SCT. We evaluated day 30 lymphocyte and platelet count (cat-
egorized at the respectivemedians: 760 109/L and 80 109/L), age,
cytogenetics, disease status at transplant, ﬁrst remission duration, and
grade II-IV acute GVHD (a-GVHD) and chronic GVHD as time-
dependent variables.Results: 51/54 patients were alive by day 30, and
47/51 (92%) had achieved a CR; 40/44 patients tested achieved 100%
donor chimerism. Actuarial survival for these 47 patients in CR was
51% and disease progression 36% at 3 years. Grade II-IV a-GVHD
was the only signiﬁcant predictor of mortality at 3 years (HR  2.8,
P .02). Disease status of NoCR/CB at PBSCT (HR 2.3, 95% CI
0.9-6), lymphocyte (HR  1.8, 95% CI 0.8-4) and platelet count
below the median (HR  1.6, 95% CI 0.7-4) showed a trend for
higher mortality. Disease status of NoCR/CB at PBSCTwas the only
signiﬁcant predictor of disease progression (HR  4.6, P  .003).
Lymphocyte count below the median showed a trend for higher
progression rate (HR  2.8, 95% CI (0.96-8)), in contrast to low
platelet count (HR 1.1 (95%CI 0.4-3)). A stratiﬁed analysis showed
that patients who were in CR at PBSCT achieved the highest count
on average, followed by the NoCR/NoCB and the NoCR/CB groups
(Table 1). A similar pattern was observed excluding patients diagnosed
with a-GVHD by day 30, or stratifying by the dose of melphalan in
the preparative regimen. Conclusion: Among patients in CR after
PBSCT for AML/MDS, day 30 lymphocyte and platelet counts are
highly correlated with disease status at PBSCT. This illustrates the
limited usefulness of these variables as independent predictors of
outcome and highlights theassociation of disease status at PBSCT and
delayed early lymphoid reconstitution (Table 1).
Table 1. Lymphocyte and Platelet Count (109/L) on Day 30 post
Transplant for Patients Who Were in CR at That Time According to
Disease Status at the Time of Transplant
CR
(n  15)
*No CR/No
CB
(n  19)
*No
CR/CB
(n  13)
Test for
Trend
(P Value)
Median
lymphocyte
count (range)
1010 (230–1770) 760 (220–3500) 470 (70–1820) .10
Median platelet
count (range)
114 (16–64) 75 (21–189) 61 (11–279) .03
Days to platelet
count 20K
(range)
14 (10–24) 15 (7–72) 22 (10–72) .01
Excluding patients
with a-GVHD
by day 30
n  11 n  15 n  8
Median
lymphocyte
count (range)
1030 (380–1770) 770 (260–3500) 560 (70–119) .03
Median platelet
count (range)
114 (56–164) 85 (21–189) 53 (31–121) .04
*CR: complete remission, CB: circulating blast.
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NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (NMT) IS WELL TOLERATED AND EFFECTIVE IN ASIAN PATIENTS
WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES
Chen, C.-S.1,2, Yusof, N.2, Tan, B.2, Law, P.1,2, Soh, T.G.2, Yasir, F.2,
Tan, L.K.2 1. National University of Singapore, Singapore, Singapore;
2. National University Hospital, Singapore, Singapore.
Aims:To evaluate the safety and feasibility of NMT for high risk
diseases in Asian patients excluded from conventional allogeneic
transplant due to co-morbidity, we initiated an IRB-approved pro-
tocol adapting published conditioning regimen with ﬂudarabine
(day 4 to 2, total 90 mg/m2) and TBI (day 0, 200 cGy).
However, GVHD prophylaxis was modiﬁed with the combination
of cyclosporin, mycophenolate mofetil and methotrexate (day 1, 3,
6, and 11). IVIG was given bi-weekly until day 100. Methods: 13
eligible patients with matched sibling donors (10/3 M/F) enrolled
with median age 42 (range: 19-62). Peripheral blood stem cells
were collected after G-CSF mobilization. Diseases included my-
elodysplastic syndrome (MDS-RA and RAEBT) (n  5), multiple
myeloma (MM) (4), acute myeloid leukemia (AML) (3) and chronic
myeloid leukemia (CML) (1). Among 5 MDS, one MDS-RA pa-
tient had end stage renal failure (IgA nephropathy) on daily peri-
toneal dialysis and one had aplastic marrow not recovering after
initial induction chemotherapy. All MM patients had failed previ-
ous autologous transplants with one failed both autologous and
allogeneic transplants. Among AML patients, one had compro-
mised cardiac function unable to complete induction chemother-
apy; one had chronic hepatitis, and one with transformed AML
who did not have consolidation chemotherapy prior to transplant.
Results: A median dose of 4.71  106 CD34 cells/kg (3.05-8.15)
and 3.69  108 CD3 T cells/kg (1.85-8.12) was infused after
conditioning. Absolute neutrophil counts fell below 500/l for all
except one patient and the median duration of neutropenia was 14
days (0-20). Only 4 patients experienced thrombocytopenia (plate-
let 20000/l) and required transfusions of 2 units (median, range
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2-9). Acute GvHD (grade I, at day 47 and day 97 [patient who
had prior allogeneic transplant with chronic GvHD]) was observed
in 2 patients while mild chronic GvHD in 7 (grade II, one due to
donor lymphocyte infusion). With a median follow-up of 13.5
months (9.5-20), 12 patients were alive and 9 remained in CR. No
transplant related mortality was seen but 2 AML patients had early
relapsed (day 59, and 130). Conclusion: The NMT regimen
with triple GVHD prophylaxis appears to be safe with no trans-
plant related mortality. It may be an effective treatment for hema-
tological malignancies in Asian patients with high risk features.
Longer follow-up and additional patients are required to conﬁrm
the efﬁcacy.
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SEQUENTIAL ADMINISTRATION OF SARGRAMOSTIM (GM-CSF) AND
FILGRASTIM (G-CSF) IN PEDIATRIC ALLOGENEIC STEM CELL TRANS-
PLANT (AlloSCT) RECIPIENTS UNDERGOING MYELOABLATIVE (MA)
CONDITIONING: COST-EFFECTIVE AND MORE RAPID PLATELET RE-
COVERY IN UCB RECIPIENTS
Militano, O.1, Boskoff, B.2, Del Toro, G.3, van deVen, C.3,
Satwani, P.3, Bradley, B.3, George, D.3, Garvin, J.H.3, Bhatia, M.3,
Roman, E.3, Wolownik, K.3, Foley, S.3, Hawks, R.3, Shwartz, J.4,
Cheung, K.5, Cairo, M.S.3,4,6 1. Department of Pharmacy, New York
Presbyterian Hospital, New York, NY; 2. Vanderbilt University, Nash-
ville, TN; 3. Department of Pediatrics, Columbia University, New York,
NY; 4. Department of Pathology, Columbia University, New York, NY;
5. Department of Biostatistics, Columbia University, New York, NY; 6.
Department of Medicine, Columbia University, New York, NY.
G-CSF or GM-CSF can hasten myeloid engraftment post MA
AlloSCT. GM-CSF is an earlier and broader acting CSF, which
also induces more TH1. DC1 immune subsets preferentially
compared to G-CSF. The objective of this study is to evaluate
efﬁcacy/safety of sequential administration of GM-CSF fol-
lowed by G-CSF in children s/p MA AlloSCT. From 1/01-6/05
we enrolled 34 children: mean age 7.2 yrs; wt 32.3 kg; M:F 
19:15; poor:average risk  13:21, TBI vs non-TBI based con-
ditioning  12:22; MFD vs umbilical cord blood (UCB) 
12:22. Indications for AlloSCT included malignant (MDS,
ALL, AML, APL, NHL [n  22]) and non-malignant (SAA,
HLH, SCD, B-thal [n  12]) disorders. GM-CSF (250 g/m2
IV QD) was initiated on day 0 post stem cell infusion. GM-CSF
was switched to G-CSF (10 g/kg IV QD) when WBC 300/
mm3  2 days. G-CSF was continued until ANC 2500/mm3 
2 days, then tapered to maintain ANC 1000/mm3. GVHD
prophylaxis: tacrolimus (target 5-20 ng/mL) and mycophenolate
as previously described (Osunkwo/Cairo, BBMT 2004). All pts
were prophylaxed against PCP, HSV, CMV, and fungal infec-
tions. There were no statistically signiﬁcant differences in base-
line characteristics between MFD vs UCB groups. Mean
CD34 cell dose/kg  36.3  105 and TNC dose/kg  39.3 
107. Median time to WBC 300/mm3  15.5 d (10 vs 19.5 d
MFD vs UCB). Median time of switch from GM-CSF (WBC
300/mm3) to G-CSF and myeloid engraftment (ANC 500/
mm3  2 d) was 0.5 d (1.5 vs 3.5 d MFD vs UCB). Median time
to myeloid and platelet engraftment (untransfused count
20000/mm3  7 d) were 17 d (13 vs 23.5 d MFD vs UCB) and
28 d (19 vs 33.5 d MFD vs UCB). Kaplan-Meier probability of
1 year OS was 67.2% (CI: 50.3-84.1). Adverse events attribut-
able to G-CSF (n  1) or GM-CSF (n  3) were: bone pain,
pleural and pericardial effusions. Of these, 3/4 pts received
concomitant oprelvekin (IL-11). Infections occurring prior to
day 60 included 21 (62%) pts with CVL bacteremia (coagulase
() staphylococci [n  9], gram () bacilli [n  10]) and 2 (6%)
pts with invasive fungal infections. This pilot study demon-
strated safety and efﬁcacy of sequential GM-CSF/G-CSF ad-
ministration in pediatric AlloSCT recipients. Myeloid recovery
after WBC 300/mm3 on GM-CSF only took 1-3 days after
switch to G-CSF. Platelet engraftment following UCBT ap-
pears more rapid with sequential GM-CSF/G-CSF compared to
historical controls. Sequential GM-CSF/G-CSF may be more
cost-effective than G-CSF alone (cost-saving of $1402/patient
based on 2004 Red Book AWP).
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR THE TREAT-
MENT OF 15 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLO-
BINURIA (PNH) IN BRAZIL
Oliveira, M.M., Bonﬁm, C., Bitencourt, M., Funke, V., Setubal, D.,
Ruiz, J., Medeiros, C.R., Zanis-Neto, J., Pasquini, R. Federal Univer-
sity of Parana, Curitiba, PR, Brazil.
PNH is a clonal disorder caused by acquired mutations of the
PIG-A gene. Many pts achieve long term survival if adverse
factors are not present. SCT can be curative for young pts with
severe pancytopenia, massive hemolysis, thrombotic complica-
tions or leukemic transformation. SCT complications are fre-
quent reported due to an increased risk of graft failure and
transplant related mortality. In this study we retrospectively
analyze 15 pts with PNH submitted to SCT in our BMT center.
Period: 03/88-02/05. Indication for SCT: severe pancytopenia:
12 pts, thrombosis: 2 pts and hemolysis: 1 pt. Age: 14-42 y (M:
29 y). Gender: 6F/9M. Time from diagnosis to SCT ranged
from 2 to 133 months (M: 29.5 mo). Previous blood transfu-
sions: 25 UI (range: 8-200 UI). Total nucleated cell infused:
1.72-4.56  108/kg (median: 2.7). Donor type: HLA identical
siblings: 14 pts, unrelated identical donor: 1 pt. Stem cell
source: bone marrow: 14 pts; peripheral blood: 1 pt. Preparatory
regimen: busulfan (BU) 12 mg/kg  cyclophosphamide (CY)
120 mg/kg: 11 pts (1 pt received BU 16 mg/kg), BU 8 mg/kg 
ﬂudarabine 125 mg/m2: 2 pts; CY 120 mg/kg  TBI ATG: 1
pt and CY 200 mg/kg: 1 pt. GVHD prophylaxis: methotrexate 
cyclosporine: 12 pts; others: 3 pts. Eleven pts are alive without
evidence of PNH with a median follow-up of 1691 days (range:
125-5998 days). Estimated 5 year survival: 73%. Two pts died
before day 28 and were not evaluable for engraftment. 13 pts
engrafted and the median time to reach ANC 	500/l was 19
days (range: 14-25). Mucositis grade III-IV occurred in 7 pts.
Two patients developed grade III-IV acute GVHD. One pt had
progressive extensive chronic GVHD and another one had de
novo extensive C-GVHD. No pt developed veno-occlusive dis-
ease. Four pts (median age of 36.5 yr) died on day 10, 11,
71 and 330 after SCT. Causes of death included infection (2
pts) and GVHD (2 pts).We conclude that pts with PNH and life
threatening complications can achieve long term survival after
SCT when HLA identical donors are used. In this group of
patents we did not observe signiﬁcant transplant related com-
plications.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
NON-HODGKIN’S LYMPHOMA IN QUEEN MARY HOSPITAL—A SINGLE
CENTRE EXPERIENCE
Lie, A.K.W., Leung, A.Y.H., Liang, R. Division of Hematology and
Bone Marrow Transplantation, The University of Hong Kong, Hong
Kong.
Objectives: Non-Hodgkin’s lymphoma (NHL) is one of the
major indications for haematopoietic stem cell transplantation
(HSCT). For chemo-sensitive relapsed cases, autologous HSCT is
often the treatment of choice. Relapsed cases after autologous
HSCT as well as those with extensive disease generally have poor
prognosis and allogeneic HSCT becomes the only option for a
cure. We summarized our experience in Queen Mary Hospital
regarding the outcome of allogeneic HSCT for this disease.Meth-
ods: Hospital records of allogeneic HSCT for underlying NHL in
the past fourteen years were retrieved. Clinical data were summa-
rized according to the pre-HSCT characteristics, disease relapse
and transplant-related mortality. Event-free (deﬁned as either dis-
ease relapse or death after HSCT) and overall survival were eval-
uated by Kaplan-Meier analysis. Results: Since 1991, a total of 48
NHL patients (M:F 25:23) have undergone allogeneic HSCT. The
median age was 42 (range: 23-63 years). Histological diagnoses
were obtained from 40 patients and they comprised both B-cell
(Burkitt or Burkitt-like  5, diffuse large B-cells  19, follicular 
3, maltoma  1, Mantle cell  3) or T-cell lymphoma (angioim-
munoblastic T-cell  3, T-lymphoblastic  4, peripheral T-cell 
2). Allogeneic HSCT was performed mostly as salvage therapy for
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